靶向叶酸受体α(FRα)的抗体药物偶联物(ADC)mirvetuximab soravtansine联合贝伐珠单抗治疗铂耐药卵巢癌患者的安全性与疗效
本研究评估mirvetuximab soravtansine联合贝伐珠单抗在铂耐药卵巢癌患者中的抗肿瘤活性与安全性。94例患者接受联合治疗,确认客观缓解率为44%(95%CI 33,54),中位缓解持续时间9.7个月,中位无进展生存期8.2个月。联合方案在FRα表达铂耐药卵巢癌中具有活性且耐受性良好。
要点
- 确认客观缓解率为44%(95%CI 33,54),含5例完全缓解。
- 中位缓解持续时间9.7个月(95%CI 6.9,14.1),中位无进展生存期8.2个月(95%CI 6.8,10.0)。
- 常见治疗相关不良事件为视力模糊(57%)、腹泻(54%)和恶心(51%),3级各1%。
核心结论
- mirvetuximab soravtansine联合贝伐珠单抗双药方案在FRα表达铂耐药卵巢癌患者中具有活性且耐受性良好。
- 无论FRα表达水平或既往是否使用贝伐珠单抗,均观察到有前景的活性。
- 这些数据强调mirvetuximab soravtansine有望成为该场景下贝伐珠单抗的首选联合搭档。
研究设计与样本
- 研究评估mirvetuximab soravtansine联合贝伐珠单抗在铂耐药卵巢癌患者中的抗肿瘤活性与安全性。
- 纳入复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,最近无铂间期≤6个月。
- 给药方案为mirvetuximab soravtansine(6 mg/kg,调整理想体重)联合贝伐珠单抗(15 mg/kg),静脉注射,每3周一次。
- 入组要求免疫组化(IHC)显示FRα表达(≥25%的细胞强度≥2+),允许既往接受贝伐珠单抗和/或PARP抑制剂(PARPi)治疗。
- 共94例患者接受联合治疗,中位年龄62岁(范围39-81)。
主要发现
- 52%的患者既往接受≥3线治疗,59%既往接受贝伐珠单抗,27%既往接受PARPi。
- 确认客观缓解率为44%(95%CI 33,54),其中5例完全缓解。
- 中位缓解持续时间为9.7个月(95%CI 6.9,14.1),中位无进展生存期为8.2个月(95%CI 6.8,10.0)。
- 治疗相关不良事件与各药物已知特征一致,最常见为视力模糊(所有级别57%;3级1%)、腹泻(54%;3级1%)和恶心(51%;3级1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer. METHODS: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months, were administered mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, once every 3 weeks. Eligibility included FRα expression by immunohistochemistry (IHC; ≥25% of cells with ≥2+ intensity). Prior bevacizumab and/or PARP inhibitor (PARPi) treatment were permitted. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety. RESULTS: Ninety-four patients received combination treatment with mirvetuximab soravtansine and bevacizumab. Median age was 62 years (range, 39-81). Fifty-two percent had ≥3 prior therapies; 59% had prior bevacizumab; and 27% had prior PARPi. ORR was 44% (95% CI 33, 54) with 5 complete responses, median DOR 9.7 months (95% CI 6.9, 14.1), and median PFS 8.2 months (95% CI 6.8, 10.0). Treatment-related adverse events were consistent with the profiles of each agent, with the most common being blurred vision (all grades 57%; grade 3, 1%), diarrhea (54%; grade 3, 1%), and nausea (51%; grade 3, 1%). CONCLUSION: The mirvetuximab soravtansine plus bevacizumab doublet is an active and well-tolerated regimen in patients with FRα-expressing platinum-resistant ovarian cancer. Promising activity was observed for patients regardless of level of FRα expression or prior bevacizumab. These data underscore the potential for mirvetuximab soravtansine as the combination partner of choice for bevacizumab in this setting.
引用
- Gilbert L, Oaknin A, Matulonis UA, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023. PMID: 36736157. doi:10.1016/j.ygyno.2023.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。